Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The investigators will follow a single prospective cohort of 50 Health Care Workers in the Hospital Italiano de Buenos Aires (Argentina) from May 15th to August 31st 2020 using antibody testing for SARS-CoV-2 IgM and IgG at baseline and every 2 weeks in order to assess the incidence of COVID-19, the prevalence of anti-SARS-CoV-2 antibodies (IgM and IgG) and incidence of reinfection or reactivations of previous COVID-19 using viral gene sequencing in this cohort.
Description: Patients that has a positive result for IgM or IgG at baseline first test
Measure: Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel Time: Baseline at study inclussionDescription: Patients that has a positive result for IgM or IgG or PCR during follow up
Measure: COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus Time: During 3 months follow upDescription: Patients with confirmed previous SARS Cov 2 antibodies that reactivate symptomons or new increase in antibodies title during follow up
Measure: Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2 Time: During 3 months follow up